Revenio Group Oyj, Stock Exchange Release, August 5, 2015 at 12:00
Revenio to renew its Management Team
Revenio Group Corporation's Board of Directors has made a decision to grow the Group's Management Team as Revenio according to its strategy focuses to health technology.
As of August 6, 2015 Revenio's Management Team is following: CEO Olli-Pekka Salovaara (chair), Icare Finland's CEO Timo Hilden, Revenio Group's CFO Robin Pulkkinen and new members, Icare Finland's Sales and Marketing Director Tomi Karvo, Icare Finland's R&D Director Ari Kukkonen and as an external communications specialist Tiina Olkkonen.
"I am pleased that the new Management Team is now completed. The abovementioned individuals have been nominated as Management Team members due to their ability to develop international business and coach Revenio as an energetic team towards our target. In addition to Icare and eye pressure measurements we are determined to launch new innovative products and methods for screening and follow up of public health's fundamental diseases. Our intention is to further improve the quality and lifetime prognosis of people globally. Our Management Team has an important role in our mission and I wish the whole team success in this important task," states Revenio Group's CEO Olli-Pekka Salovaara.
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.